FDA to Review Sandoz's Generic GLP-1 Drugs

Although GOOGL shares fell 2.9% in the last close and the RSI is approaching oversold territory at 33.4, MACD values remain negative and below the signal line. While the news headline does not directly involve Alphabet, the FDA review of generic GLP-1 drugs could indirectly pressure Alphabet's health technology investments, such as Verily. In the short term, technical indicators remain weak, and the gap between the 20-day SMA (343.27) and the 50-day SMA (351.35) is widening, suggesting the downtrend may continue. However, the RSI approaching oversold territory could signal a potential buying opportunity, though momentum does not yet support a reversal.

The news poses a potential threat to Novo Nordisk's dominance in the GLP-1 market. Sandoz's generic GLP-1 drugs under FDA review raise concerns that competition may increase. Technically, the RSI is near overbought territory at 64.8, and the MACD has crossed below its signal line, which could signal a short-term correction. Although the stock rose 2.7% in the last 24 hours, profit-taking may occur with this news. A downward movement is expected in the short term.

The FDA review of Sandoz’s GLP‑1 generics may relieve pricing pressure on Eli Lilly’s branded product, Trulicity, creating a short‑term positive effect. However, as the review process has not yet concluded, the market has not yet settled on a clear direction. Technical indicators point to a strong bullish momentum, yet the RSI sits at 79, placing it in an overbought zone and raising the likelihood of a short‑term correction. Consequently, the impact of the current news may remain neutral in the near term, but investors should consider the possibility of a price pullback following a brief rebound.